Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06064006 · ClinicalTrials.gov registry record · Phase 2

A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin

A Phase 2 study, sponsored by Novo Nordisk A/S.

Completed
Registry status
Phase 2
Development phase
125
Enrollment target

NCT06064006 is a Phase 2 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 125 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06064006, a Phase 2 study, has completed, sponsored by Novo Nordisk A/S.

COMPLETED
Registry status
Phase 2
Development phase
125 participants
Enrollment target

Study Summary

The purpose of the study is to evaluate if a new study drug, NNC0487-0111, is safe and how it works in the participant's body, when given as injections under the skin

Interventions

  • DRUG NNC0487-0111
  • DRUG Placebo (NNC0487-0111)

Trial Details

FieldValue
Enrollment Target 125 participants
Start Date 2023-09-15
Est. Completion 2024-11-27
Phase Phase 2

Sponsor

Novo Nordisk A/S

431 total trials

What the Registry Record Tells You About NCT06064006

The ClinicalTrials.gov registry entry for NCT06064006 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which NNC0487-0111 is the first listed.

NCT06064006 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT06064006 about?

NCT06064006 is a clinical study titled "A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin". The purpose of the study is to evaluate if a new study drug, NNC0487-0111, is safe and how it works in the participant's body, when given as injections under the skin

What is the current status of trial NCT06064006?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2023-09-15. Estimated completion is 2024-11-27.

What interventions are being tested in trial NCT06064006?

The interventions under investigation include: NNC0487-0111 (DRUG), Placebo (NNC0487-0111) (DRUG).

Who is sponsoring clinical trial NCT06064006?

This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.